Merck (NYSE: MRK) announced results from the Phase 3 LITESPARK-022 trial showing that KEYTRUDA (pembrolizumab) combined with WELIREG (belzutifan) reduced ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE